Education Hepatology – Chronic Hepatitis C

Vanguard Report: Translational Science, Outcomes, Viral Hepatitis

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Anes/CCM
- Basic Science
- Bhat M
- 2018 ELITA & LICAGE Lisbon
Vanguard Report: Marginal Candidate, Viral Hepatitis, Immunosuppression

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Acute liver failure
- Anes/CCM
- de Martin E
- 2018 ELITA & LICAGE Lisbon
Gilead Sponsored Symposium: HCV and Nonhepatic Solid Organ Transplant: Focus on Renal, Heart, and Lung Transplant

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Paul Kwo
- 2015 ILTS Chicago
Gilead Sponsored Symposium: Case Presentation:IFN-free Therapy in the Pre-transplant Setting

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Paul Kwo
- 2015 ILTS Chicago
Gilead Sponsored Symposium: HCV Pharmacotherapy: Efficacy in the Pre- and Post-transplant Settings

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Steven L. Flamm
- 2015 ILTS Chicago
Gilead Sponsored Symposium: Managing HCV in Liver Transplantation: Reframing the Paradigm in the Context of New HCV Therapies

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Michael Abecassis
- 2015 ILTS Chicago
Gilead Sponsored Symposium: Managing HCV in Liver Transplantation: Optimizing Success with new DAA Regimens

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Paul Kwo
- 2015 ILTS Chicago
Questions and Answers in Viral Hepatitis: Hepatitis E: Should We Care?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis B
- Chronic Hepatitis C
- Lionel Rostaing
- 2015 ILTS Chicago
Questions and Answers in Viral Hepatitis: Hepatitis C: What?s New in Post-Transplant Therapy?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Helen Te
- 2015 ILTS Chicago
Questions and Answers in Viral Hepatitis: Hepatitis C: What?s New in Pre-Transplant Therapy?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Michael Curry
- 2015 ILTS Chicago
DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Drug Interaction for HCV Post Liver Transplant – Debate – CON

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Didier Samuel
- 2014 ILTS/ELITA/LICAGE London
DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Drug Interaction for HCV Post Liver Transplant – Debate – PRO

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Michael Charlton
- 2014 ILTS/ELITA/LICAGE London
DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Post-transplant: Who and When?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Robert Brown
- 2014 ILTS/ELITA/LICAGE London
DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: A Lead into Transplantation

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Marina Berenguer
- 2014 ILTS/ELITA/LICAGE London
VANGUARD GRAND ROUND CASE PRESENTATIONS: Use of New Antiviral Therapies Before and After Liver Transplantation for HCV?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Patrizia Burra
- 2014 ILTS/ELITA/LICAGE London
HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: Interferon-free Regimens Pre- and Post-Transplant

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Immunosuppression / rejection
- Michael Charlton
- 2013 ILTS Sydney
HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: Triple Therapy with Boceprevir/Telaprevir Before and After Transplantation

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Professor Didier Samuel
- 2013 ILTS Sydney
HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: What are the Key Influences on Outcome in the Pre-DAA Era?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Marina Berenguer
- 2013 ILTS Sydney
ARE THERE CONTINUING CHALLENGES REGARDING ALLOGRAFT REJECTION?: Do Allograft Responses Affect HCV Recurrence?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Chronic Hepatitis C
- Immunosuppression / rejection
- Hideki Ohdan
- 2013 ILTS Sydney

International Liver Transplantation Society

The knowledge network for liver transplantation

Education Hepatology – Chronic Hepatitis C

Vanguard Report: Translational Science, Outcomes, Viral Hepatitis

Vanguard Report: Marginal Candidate, Viral Hepatitis, Immunosuppression

Gilead Sponsored Symposium: HCV and Nonhepatic Solid Organ Transplant: Focus on Renal, Heart, and Lung Transplant

Gilead Sponsored Symposium: Case Presentation:IFN-free Therapy in the Pre-transplant Setting

Gilead Sponsored Symposium: HCV Pharmacotherapy: Efficacy in the Pre- and Post-transplant Settings

Gilead Sponsored Symposium: Managing HCV in Liver Transplantation: Reframing the Paradigm in the Context of New HCV Therapies

Gilead Sponsored Symposium: Managing HCV in Liver Transplantation: Optimizing Success with new DAA Regimens

Questions and Answers in Viral Hepatitis: Hepatitis E: Should We Care?

Questions and Answers in Viral Hepatitis: Hepatitis C: What?s New in Post-Transplant Therapy?

Questions and Answers in Viral Hepatitis: Hepatitis C: What?s New in Pre-Transplant Therapy?

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Drug Interaction for HCV Post Liver Transplant – Debate – CON

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Drug Interaction for HCV Post Liver Transplant – Debate – PRO

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Post-transplant: Who and When?

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: A Lead into Transplantation

VANGUARD GRAND ROUND CASE PRESENTATIONS: Use of New Antiviral Therapies Before and After Liver Transplantation for HCV?

HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: Interferon-free Regimens Pre- and Post-Transplant

HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: Triple Therapy with Boceprevir/Telaprevir Before and After Transplantation

HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: What are the Key Influences on Outcome in the Pre-DAA Era?

ARE THERE CONTINUING CHALLENGES REGARDING ALLOGRAFT REJECTION?: Do Allograft Responses Affect HCV Recurrence?

Specialty Sections

Content Directories

International Liver Transplantation Society

The knowledge network for liver transplantation

Education Hepatology – Chronic Hepatitis C

Vanguard Report: Translational Science, Outcomes, Viral Hepatitis

Vanguard Report: Marginal Candidate, Viral Hepatitis, Immunosuppression

Gilead Sponsored Symposium: HCV and Nonhepatic Solid Organ Transplant: Focus on Renal, Heart, and Lung Transplant

Gilead Sponsored Symposium: Case Presentation: IFN-free Therapy in the Pre-transplant Setting

Gilead Sponsored Symposium: HCV Pharmacotherapy: Efficacy in the Pre- and Post-transplant Settings

Gilead Sponsored Symposium: Managing HCV in Liver Transplantation: Reframing the Paradigm in the Context of New HCV Therapies

Gilead Sponsored Symposium: Managing HCV in Liver Transplantation: Optimizing Success with new DAA Regimens

Questions and Answers in Viral Hepatitis: Hepatitis E: Should We Care?

Questions and Answers in Viral Hepatitis: Hepatitis C: What?s New in Post-Transplant Therapy?

Questions and Answers in Viral Hepatitis: Hepatitis C: What?s New in Pre-Transplant Therapy?

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Drug Interaction for HCV Post Liver Transplant – Debate – CON

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Drug Interaction for HCV Post Liver Transplant – Debate – PRO

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: Post-transplant: Who and When?

DIRECTED ANTIVIRAL THERAPY FOR HEPATITIS C: A Lead into Transplantation

VANGUARD GRAND ROUND CASE PRESENTATIONS: Use of New Antiviral Therapies Before and After Liver Transplantation for HCV?

HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: Interferon-free Regimens Pre- and Post-Transplant

HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: Triple Therapy with Boceprevir/Telaprevir Before and After Transplantation

HCV IN THE LIVER TRANSPLANT SETTING: WHERE ARE WE UP TO?: What are the Key Influences on Outcome in the Pre-DAA Era?

ARE THERE CONTINUING CHALLENGES REGARDING ALLOGRAFT REJECTION?: Do Allograft Responses Affect HCV Recurrence?

Specialty Sections

Content Directories

Gilead Sponsored Symposium: Case Presentation:IFN-free Therapy in the Pre-transplant Setting